A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A naturalistic cohort study of first-episode schizophrenia spectrum disorder : A description of the early phase of illness in the PSYSCAN cohort. / Slot, Margot I.E.; van Hell, Hendrika H.; Rossum, Inge Winter van; Dazzan, Paola; Maat, Arija; de Haan, Lieuwe; Crespo-Facorro, Benedicto; Glenthøj, Birte; Lawrie, Stephen M.; McDonald, Colm; Gruber, Oliver; van Amelsvoort, Thérèse; Arango, Celso; Kircher, Tilo; Nelson, Barnaby; Galderisi, Silvana; Weiser, Mark; Sachs, Gabriele; Maatz, Anke; Bressan, Rodrigo A.; Kwon, Jun Soo; Mizrahi, Romina; McGuire, Philip; Kahn, René S.; the PSYSCAN Consortium.
In: Schizophrenia Research, Vol. 266, 2024, p. 237-248.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A naturalistic cohort study of first-episode schizophrenia spectrum disorder
T2 - A description of the early phase of illness in the PSYSCAN cohort
AU - Slot, Margot I.E.
AU - van Hell, Hendrika H.
AU - Rossum, Inge Winter van
AU - Dazzan, Paola
AU - Maat, Arija
AU - de Haan, Lieuwe
AU - Crespo-Facorro, Benedicto
AU - Glenthøj, Birte
AU - Lawrie, Stephen M.
AU - McDonald, Colm
AU - Gruber, Oliver
AU - van Amelsvoort, Thérèse
AU - Arango, Celso
AU - Kircher, Tilo
AU - Nelson, Barnaby
AU - Galderisi, Silvana
AU - Weiser, Mark
AU - Sachs, Gabriele
AU - Maatz, Anke
AU - Bressan, Rodrigo A.
AU - Kwon, Jun Soo
AU - Mizrahi, Romina
AU - McGuire, Philip
AU - Kahn, René S.
AU - the PSYSCAN Consortium
N1 - Publisher Copyright: © 2024 The Authors
PY - 2024
Y1 - 2024
N2 - Background: We examined the course of illness over a 12-month period in a large, international multi-center cohort of people with a first-episode schizophrenia spectrum disorder (FES) in a naturalistic, prospective study (PSYSCAN). Method: Patients with a first episode of schizophrenia, schizoaffective disorder (depressive type) or schizophreniform disorder were recruited at 16 institutions in Europe, Israel and Australia. Participants (N = 304) received clinical treatment as usual throughout the study. Results: The mean age of the cohort was 24.3 years (SD = 5.6), and 67 % were male. At baseline, participants presented with a range of intensities of psychotic symptoms, 80 % were taking antipsychotic medication, 68 % were receiving psychological treatment, with 46.5 % in symptomatic remission. The mean duration of untreated psychosis was 6.2 months (SD = 17.0). After one year, 67 % were in symptomatic remission and 61 % were in functional remission, but 31 % had been readmitted to hospital at some time after baseline. In the cohort as a whole, depressive symptoms remained stable over the follow-up period. In patients with a current depressive episode at baseline, depressive symptoms slightly improved. Alcohol, tobacco and cannabis were the most commonly used substances, with daily users of cannabis ranging between 9 and 11 % throughout the follow-up period. Conclusions: This study provides valuable insight into the early course of a broad range of clinical and functional aspects of illness in FES patients in routine clinical practice.
AB - Background: We examined the course of illness over a 12-month period in a large, international multi-center cohort of people with a first-episode schizophrenia spectrum disorder (FES) in a naturalistic, prospective study (PSYSCAN). Method: Patients with a first episode of schizophrenia, schizoaffective disorder (depressive type) or schizophreniform disorder were recruited at 16 institutions in Europe, Israel and Australia. Participants (N = 304) received clinical treatment as usual throughout the study. Results: The mean age of the cohort was 24.3 years (SD = 5.6), and 67 % were male. At baseline, participants presented with a range of intensities of psychotic symptoms, 80 % were taking antipsychotic medication, 68 % were receiving psychological treatment, with 46.5 % in symptomatic remission. The mean duration of untreated psychosis was 6.2 months (SD = 17.0). After one year, 67 % were in symptomatic remission and 61 % were in functional remission, but 31 % had been readmitted to hospital at some time after baseline. In the cohort as a whole, depressive symptoms remained stable over the follow-up period. In patients with a current depressive episode at baseline, depressive symptoms slightly improved. Alcohol, tobacco and cannabis were the most commonly used substances, with daily users of cannabis ranging between 9 and 11 % throughout the follow-up period. Conclusions: This study provides valuable insight into the early course of a broad range of clinical and functional aspects of illness in FES patients in routine clinical practice.
KW - First episode psychosis
KW - Functioning
KW - Longitudinal study
KW - PSYSCAN
KW - Remission
KW - Schizophrenia
U2 - 10.1016/j.schres.2024.02.018
DO - 10.1016/j.schres.2024.02.018
M3 - Journal article
C2 - 38431986
AN - SCOPUS:85186341470
VL - 266
SP - 237
EP - 248
JO - Schizophrenia Research
JF - Schizophrenia Research
SN - 0920-9964
ER -
ID: 386493889